Prohost Letter #428
End of the Year Decisions ~ Part 3
In Part 3 of this series we selected two firms, both were recently added to the Prohost Portfolio. The first firm, FortySeven (FTSV), focuses on an immunotherapy that differs from the breakthrough blockbuster checkpoint inhibitors on the surface of the T Cells. FortySeven’s products target checkpoint proteins on both cancer cells and macrophage cells. The latter cells are major players in the innate immune system. The outcome of FortySeven’s approach is expected . . .